Transitional Cell Carcinoma malady

Wikipedia: Transitional cell carcinoma (TCC, also urothelial cell carcinoma or UCC) is a type of cancer that...⁴⁴ more...

MalaCards: Transitional Cell Carcinoma, also known as transitional cell carcinoma nos (morphologic abnormality), is related to carcinoma and invasive bladder transitional cell carcinoma. An important gene associated with Transitional Cell Carcinoma is UPK2 (uroplakin 2), and among its related pathways are Melanoma and p53 signaling pathway. The compounds sucrose and b 723 have been mentioned in the context of this disorder. Affiliated tissues include kidney, lung and ovary, and related mouse phenotypes are mortality/aging and embryogenesis.

Disease Ontology: A carcinoma that derives from transitional epithelial cells.⁶

Aliases & Descriptions:

transitional cell carcinoma 6 30 8 transitional cell carcinoma nos (morphologic abnormality) 6 transitional cell carcinoma (morphologic abnormality) 6 transitional cell neoplasm (morphologic abnormality) 6 transitional cell carcinoma of the urinary tract 6

carcinoma, transitional cell 43 carcinoma transitional cell 32 transitional cell neoplasm 43 transitional cell tumor 6 transitional carcinoma 6

Diseases related to transitional cell carcinoma by text searches and GeneDecks gene sharing:

(show top 50)    (show all 936)

id	Related Disease	Score	Top Affiliating Genes
1	carcinoma	40.8	KLF6, CNTN2, WARS, KIT, KISS1, KISS1R
2	invasive bladder transitional cell carcinoma	34.4	CDKN1A, IFI27, ERBB2, TP53, EGFR
3	urinary bladder cancer	34.3	SFRP1, RB1, NAT1, NAT2, BIRC5, KDR
4	dna topoisomerase ii	33.0	PCNA, BCL2L1, CDKN1A, MKI67, GSTP1, IFI27
5	rectal cloacogenic carcinoma	33.0	PCNA, RB1, BSG, NAT1, NAT2, VEGFC
6	squamous cell carcinoma	32.9	SERPINB3, PAK1, LGALS1, LGALS3, CD44, CDH1
7	bladder urothelial papillary carcinoma	32.1	VEGFC, BIRC5, CGB5, CDH1, MKI67, FHIT
8	renal cell carcinoma	31.4	KIT, KISS1, KISS1R, SFRP1, PCNA, VIM
9	bladder squamous cell carcinoma	31.2	SFN, UPK2, FABP5, FABP12, KRT5, KRT14
10	dna topoisomerase i	31.1	CNTN2, PARP1, CDKN2A, CD40LG, CDK4, MKI67
11	ovarian brenner tumor	30.8	UPK3A, MUC16, KRT13, KRT7, KRT20, THBD
12	papillary adenocarcinoma	30.8	MUC1, MUC16, CGB5, CEACAM5, SLC2A1, NME1
13	small cell carcinoma	30.5	KLF6, KIT, PCNA, RB1, VIM, VEGFA
14	neuroepithelioma	30.3	B2M, CD99, GRP, ENO2, MAPK10, IGFBP2
15	bladder carcinoma	29.7	SFN, PCNA, RB1, VIM, BSG, NAT1
16	prostatitis	29.6	KLF6, KIT, KISS1, SFN, SFRP1, PCNA
17	adenocarcinoma	29.3	KLF6, WARS, KIT, SFN, SFRP1, PCNA
18	papilloma	29.0	PCNA, RB1, SERPINB3, VIM, BRAF, VEGFA
19	angiosarcoma	28.9	KIT, VIM, VEGFA, VEGFC, KDR, MUC1
20	hypercalcemia	28.6	VIM, VDR, CHGA, B2M, FGF2, FGFR3
21	tuberous sclerosis	28.2	PCNA, VIM, VHL, VEGFA, BIRC5, MVP
22	retinoblastoma	26.5	KLF6, KIT, PCNA, RB1, VIM, BSG
23	hypoxia	26.5	WARS, KIT, SFRP1, PCNA, RB1, BSG
24	neuronitis	25.5	KLF6, CNTN2, KIT, KISS1, KISS1R, SFN
25	melanoma	25.4	KLF6, WARS, KIT, KISS1, KISS1R, SFN
26	blindness	25.3	VEGFA, VDR, CLU, PAX5, KDR, CHGA
27	ovarian carcinoma	25.0	KIT, KISS1, KISS1R, PCNA, RB1, VIM
28	colorectal adenoma and carcinoma	14.9	PCNA, VEGFA, BCL2, CHEK2, MUC1, BAX
29	boomerang dysplasia	14.8	PCNA, RB1, BRAF, VHL, BMPR2, CLU
30	chordoma	14.8	VIM, VEGFA, LGALS1, LGALS3, MUC1, CEACAM3
31	keratoacanthoma	14.7	PCNA, BCL2, BCL2L1, MUC1, MSH2, JUP
32	intrahepatic cholangiocarcinoma	14.7	SFN, RB1, BSG, VEGFC, BMF, BLCAP
33	gestational trophoblastic neoplasm	14.7	KISS1, PCNA, CGA, CGB, CGB5, CGB7
34	barrett's esophagus	14.7	S100A8, CDKN2A, MKI67, FHIT, GSTP1, FGF1
35	barrett's adenocarcinoma	14.7	PCNA, BRAF, VEGFA, BIRC5, XRCC1, XPC
36	diffuse astrocytoma	14.7	PCNA, BRAF, LGALS3, CDKN2A, CDK4, MKI67
37	sweat gland carcinoma	14.7	PCNA, MUC1, ERBB2, TP53, TP63, KRT8
38	vulvar cancer	14.6	CD44, IL2, MAGEA1, MAGEA4, CCND1, CASP3
39	craniopharyngioma	14.6	PCNA, VIM, LGALS1, LGALS3, CGA, CEACAM3
40	skin melanoma	14.6	PCNA, CDKN1A, CDKN2A, MMP2, MLH1, MKI67
41	intraepithelial neoplasm	14.6	PCNA, MUC1, XRCC1, CDKN2A, MKI67, ERBB2
42	anaplastic carcinoma	14.6	VIM, BRAF, LGALS1, LGALS3, MUC1, CEACAM3
43	ectopic pregnancy	14.6	CHKB, CGA, CGB, CGB5, CGB7, HSPD1
44	cervix carcinoma	14.6	CDKN1A, CDKN2A, CD44, MKI67, FGFR3, MET
45	lymphoepithelioma-like carcinoma	14.6	VIM, BCL2, MUC1, CGB, CDH1, ALPP
46	adenoameloblastoma	14.5	PCNA, BSG, CDKN1B, MMP2, CALB2, TNFRSF10B
47	maxillary sinus squamous cell carcinoma	14.5	PCNA, VEGFA, BCL2L1, BAX, CDKN1A, GSTP1
48	bannayan-riley-ruvalcaba syndrome	14.5	VIM, VHL, BCL2, LGALS1, CHGA, MUC1
49	trichoepithelioma	14.5	VIM, BCL2, CDH1, MKI67, PTCH1, KRT8
50	benign meningioma	14.5	PCNA, VIM, BIRC5, MUC1, MKI67, MDM2

Approved drugs:

Drug clinical trials:

MalaCards organs/tissues related to transitional cell carcinoma:

²²

MGI Mouse Phenotypes related to transitional cell carcinoma:

²⁵ (show all 29)

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	mortality/aging	MP:0010768	11.8	KLF6, KISS1, KISS1R, SFN, SFRP1, RB1
2	embryogenesis phenotype	MP:0005380	11.4	KLF6, KIT, SFN, SFRP1, VIM, NAT1
3	hematopoietic system phenotype	MP:0005397	11.0	KLF6, KIT, KISS1R, SFN, SFRP1, PCNA
4	reproductive system phenotype	MP:0005389	10.9	KLF6, KISS1, KISS1R, SFN, NAT1, VHL
5	respiratory system phenotype	MP:0005388	10.9	BMPR2, BDNF, BCL6, GSN, CBS, GLI3
6	immune system phenotype	MP:0005387	10.6	KIT, KISS1R, SFN, SFRP1, VIM, BSG
7	normal phenotype	MP:0002873	10.4	KISS1R, NAT1, BRAF, VHL, VEGFA, BMF
8	integument phenotype	MP:0010771	10.3	KLF6, KIT, KISS1, KISS1R, SFN, RB1
9	craniofacial phenotype	MP:0005382	10.2	KIT, BDNF, FGFR2, APAF1, CBS, GLI3
10	liver/biliary system phenotype	MP:0005370	10.0	KLF6, KIT, SFN, VHL, VEGFA, BCL6
11	nervous system phenotype	MP:0003631	9.9	CNTN2, KIT, KISS1, KISS1R, SFRP1, RB1
12	endocrine/exocrine gland phenotype	MP:0005379	9.8	KISS1, KISS1R, SFN, MXI1, MSMB, FSHB
13	digestive/alimentary phenotype	MP:0005381	9.8	KIT, KISS1, KISS1R, SFN, RB1, BRAF
14	growth/size phenotype	MP:0005378	9.8	KLF6, KIT, KISS1, KISS1R, SFN, SFRP1
15	no phenotypic analysis	MP:0003012	9.8	SFRP1, PCNA, RB1, VEGFA, BMF, PARP1
16	pigmentation phenotype	MP:0001186	9.7	KIT, RB1, BRAF, BCL2, CDKN1B, CDKN2A
17	hearing/vestibular/ear phenotype	MP:0005377	9.6	KIT, SFN, RB1, VDR, PAX5, PARP1
18	other phenotype	MP:0005395	9.4	CLU, KDR, MSR1, CDKN2A, CD40LG, ITGB1
19	renal/urinary system phenotype	MP:0005367	9.4	KIT, KISS1, KISS1R, BRAF, VHL, CLU
20	tumorigenesis	MP:0002006	9.3	KIT, SFN, RB1, BRAF, VHL, BMF
21	skeleton phenotype	MP:0005390	9.1	KIT, SFN, SFRP1, RB1, BRAF, VHL
22	muscle phenotype	MP:0005369	8.9	KIT, RB1, VIM, BRAF, VHL, VEGFA
23	limbs/digits/tail phenotype	MP:0005371	8.7	KIT, SFN, SFRP1, RB1, VHL, VEGFA
24	vision/eye phenotype	MP:0005391	8.7	KIT, SFN, RB1, VIM, NAT1, BRAF
25	cardiovascular system phenotype	MP:0005385	8.7	KLF6, KIT, SFRP1, RB1, VIM, BRAF
26	adipose tissue phenotype	MP:0005375	8.5	SFRP1, RB1, BRAF, BCL2, CDKN1A, CDKN1B
27	homeostasis/metabolism phenotype	MP:0005376	8.1	KIT, KISS1, KISS1R, SFRP1, RB1, VIM
28	behavior/neurological phenotype	MP:0005386	7.6	CNTN2, KIT, KISS1R, RB1, VIM, BRAF
29	cellular phenotype	MP:0005384	7.2	KLF6, KIT, SFN, PCNA, RB1, VIM

Articles related to transitional cell carcinoma:

(show top 50)    (show all 467)

id	Title	Authors	Year	Affiliating Genes
1	Reciprocal correlation between the expression of cycl ooxygenase-2 and E-cadherin in human bladder transitional cell carcinomas. (20582552)	Jang T.J.... Lee K.S.	2010	CDH1, PTGS2
2	Impaired delta NP63 expression is associated with poor tumor development in transitional cell carcinoma of the bladder. (18955789)	He Y.... Du H.	2008	TP63
3	Demethylating agent 5-aza-2'-deoxycytidine enhances susceptibility of bladder transitional cell carcinoma to Cisplatin. (18538698)	Shang D.... Ogawa O.	2008	DNMT1
4	Insights from a whole cystectomy specimen--association of primary small cell carcinoma of the bladder with transitional cell carcinoma in situ. (18547617)	Gaisa N.T.... KnA1chel R.	2008	TP53
5	Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: A Long-term study. (18367096)	Salinas-Sanchez A.S.... Escribano-Martinez J.	2007	TP53
6	Expression of cyclooxygenase-2, P-glycoprotein and multi-drug resistance-associated protein in canine transitional cell carcinoma. (17316722)	Lee J.Y.... Inokuma H.	2007	PTGS2
7	Overexpression of HER-2/neu oncogene and transitional cell carcinoma of bladder. (17987577)	Jalali Nadoushan M.R.... Zaeri F.	2007	ERBB2
8	Heterogeneity of cellular proliferation within transitional cell carcinoma: correlation of protein kinase C alpha/betaI expression and activity. (16517978)	Aaltonen V.... Peltonen J.	2006	PRKCA, PRKCB
9	Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract. (16609907)	Miyata Y.... Kanetake H.	2006	MMP2, PTGER4
10	Prostate stem cell antigen predicts tumour recurrence in superficial transitional cell carcinoma of the urinary bladder. (16686711)	Elsamman E.... Kanayama H.O.	2006	PSCA
11	Association of PAX5 expression with clinical outcome in patients with TaT1 transitional cell carcinoma of the bladder. (16566978)	Babjuk M.... DvorRcek J.	2006	PAX5
12	Interleukin-4 gene intron-3 polymorphism is associated with transitional cell carcinoma of the urinary bladder. (15679809)	Tsai F.J.... Chen W.C.	2005	IL4
13	Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder. (15963628)	Shariat S.F.... Stenman U.H.	2005	SPINK1
14	Accuracy of the routine detection of mutation in mismatch repair genes in patients with susceptibility to hereditary upper urinary tract transitional cell carcinoma. (15963139)	RouprA-t M.... Cussenot O.	2005	MLH1
15	Upregulated MT1-MMP/TIMP-2 axis in the TSU-Pr1-B1/B2 model of metastatic progression in transitional cell carcinoma of the bladder. (16086232)	Chaffer C.L.... Williams E.D.	2005	MMP15
16	The prognostic value of p53, Ki-67 and matrix metalloproteinases MMP-2 and MMP-9 in transitional cell carcinoma of the renal pelvis and ureter. (16351648)	Kamijima S.... Ito H.	2005	TP53, MMP9, MKI67
17	Expression of lung resistance-related protein gene in transitional cell carcinoma of the bladder (15771821)	Kong C.Z.... Li Z.L.	2005	TP63, MVP
18	Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. (15183954)	Zigeuner R.... Langner C.	2004	TP53, TP63
19	Expression of lung resistance-related protein in transitional cell carcinoma of bladder. (15072883)	Zhu Y.... Gao H.	2004	TP63, MVP
20	Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder. (15457669)	Rath-Wolfson L.... Koren R.	2004	TOP2A
21	Molecular cloning and expression of uroplakins in transitional cell carcinoma. (15088894)	Yuasa T.... Okada Y.	2003	UPK3A, UPK1A, UPK1B
22	Molecular markers for transitional cell carcinoma of bladder (12908389)	Kleinmann J.... Zisman A.	2003	KRT20
23	Multivariate analysis of recurrence in T1 bladder transitional cell carcinoma (14575574)	Zhang J.... Guo Y.L.	2003	CDH1, TP53
24	Multiple primary cancer, including transitional cell carcinoma of the upper uroepithelial tract in a multigeneration HNPCC family: molecular genetic, diagnostic, and management implications. (12650804)	Lynch H.T.... Wagner A.	2003	MSH2
25	Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. (12576817)	Shariat S.F.... Lerner S.P.	2003	PTGS2
26	Prediction of lymph node metastasis based on p53 and nm23-H1 expression in muscle invasive grade III transitional cell carcinoma of bladder. (15088897)	Park D.S.... Lee J.M.	2003	NME1
27	The expression of p53 and c-erb-2 in transitional cell carcinoma of the kidney pelvis and ureter and its relation to tumor progression and survival (12380307)	Fontana L.O.... Canteras Jordana M.	2002	ERBB2, TP53
28	Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder. (11836589)	Uchida T.... Baba S.	2002	MDM2, TP53
29	Parafallopian tube transitional cell carcinoma. (12217766)	Paner G.P.... Husain A.N.	2002	KRT7, CALB2, KRT20
30	E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma. (12395372)	Sun W.... Herrera G.A.	2002	CDH1
31	Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. (11223675)	Friedrich M.G.... Huland H.	2001	TP53
32	Prognostic significance of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine samples from patients with transitional cell carcinoma of the bladder. (11705862)	Durkan G.C.... Mellon J.K.	2001	MMP1, TIMP1
33	Changes of phenotypic expression of prostatic antigen in secondary transitional cell carcinoma of the prostate: evidence for induction phenomenon as a mechanism for acquisition of prostatic antigens in prostatic transitional cell carcinoma. (11351346)	Mai K.T.... Farmer J.	2001	ACPP
34	The expression of PAX5 in human transitional cell carcinoma of the bladder: relationship with de-differentiation. (10368252)	Adshead J.M.... Kessling A.M.	1999	PAX5
35	Prognostic significance of p53 protein overexpression in transitional cell carcinoma of the renal pelvis and ureter. (9644783)	Jinza S.... Masuda M.	1998	TP53
36	Correlation of nuclear morphometry and immunostaining for p53 and proliferating cell nuclear antigen in transitional cell carcinoma of the bladder. (9477184)	Ogura K.... Yoshida O.	1997	PCNA
37	Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-GuAcrin treatment. (9111623)	Ick K.... Fan K.	1997	TP53
38	A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer. (9264274)	Xu X.... Burns P.A.	1997	TP53
39	Detection and clinical pathological significance of the expression of P21, P185, p53 proteins and mutation of ras, p53 genes in transitional cell carcinoma of the bladder (9275651)	Yu D.... Liang Z.	1996	TP53
40	The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder. (8738404)	Fujisawa M.... Kamidono S.	1996	CDH1
41	Immunohistochemical evaluation of nm23-H1 gene product in transitional cell carcinoma of the bladder. (8735718)	Nakopoulou L.L.... Dimopoulos C.A.	1996	NME1
42	Autocrine motility factor receptor as a possible urine marker for transitional cell carcinoma of the bladder. (7490884)	Korman H.J.... Raz A.	1996	AMFR
43	Expression of CD44 splice variants in human transitional cell carcinoma. (8740026)	Takada S.... Okuyama A.	1996	CD44
44	Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. (7538603)	Hong R.L.... Lee W.J.	1995	CDH1, CD44
45	Autocrine growth of transitional cell carcinoma of the bladder induced by granulocyte-colony stimulating factor. (7542171)	Tachibana M.... Amano Y.	1995	CSF3
46	Is beta-human chorionic gonadotrophin production by transitional cell carcinoma of the bladder a marker of aggressive disease and resistance to radiotherapy? (7508330)	Moutzouris G.... Theodorou C.	1993	CGB7
47	Transitional cell carcinoma of the renal pelvis with choriocarcinomatous differentiation. Immunohistochemical and immunoelectron microscopic assessment of human chorionic gonadotropin production by transitional cell carcinoma of the urinary bladder. (8448745)	Grammatico D.... Walton J.C.	1993	CGA
48	Immunohistochemical detection of acidic fibroblast growth factor in bladder transitional cell carcinoma. (1377428)	Ravery V.... Chopin D.K.	1992	FGF1
49	Transitional cell carcinoma of the urinary bladder wi th osteoclast-type giant cells: a report of two cases and review of the literat ure. (2076867)	Zukerberg L.R.... Young R.H.	1990	VIM
50	Distribution of cytokeratin polypeptides in human transitional cell carcinomas, with special emphasis on changing expression patterns during tumor progression. (1689541)	Schaafsma H.E.... Ruiter D.J.	1990	KRT18, KRT8, CHKB

Genes related to transitional cell carcinoma according to GeneCards:

(show top 50)    (show all 287)

id	Symbol	Description	Score	GeneCards Section Context
1	UPK2	uroplakin 2	11.1	Publications, Functions, Summaries
2	PTCH1	patched 1	11.1	Publications, Summaries
3	IFI27	interferon, alpha-inducible protein 27	11.0	Publications
4	TP53	tumor protein p53	11.0	Publications
5	ERBB2	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (avian)	11.0	Publications
6	CDKN1A	cyclin-dependent kinase inhibitor 1A (p21, Cip1)	11.0	Publications
7	EGFR	epidermal growth factor receptor	11.0	Publications
8	UPK1A	uroplakin 1A	11.0	Publications, Functions
9	KRT13	keratin 13	11.0	Publications
10	BLCAP	bladder cancer associated protein	11.0	Publications
11	NR2F1	nuclear receptor subfamily 2, group F, member 1	11.0	Publications
12	C9orf9	chromosome 9 open reading frame 9	11.0
13	FABP4	fatty acid binding protein 4, adipocyte	11.0	Publications
14	FABP12	fatty acid binding protein 12	11.0	Publications
15	HPGD	hydroxyprostaglandin dehydrogenase 15-(NAD)	11.0	Publications
16	FGF3	fibroblast growth factor 3	11.0	Publications
17	FABP5	fatty acid binding protein 5 (psoriasis-associated)	11.0	Publications
18	BIRC7	baculoviral IAP repeat containing 7	11.0	Publications
19	WARS	tryptophanyl-tRNA synthetase	11.0	Publications
20	CGB	chorionic gonadotropin, beta polypeptide	11.0	Publications
21	ADAM28	ADAM metallopeptidase domain 28	11.0	Publications
22	MMP10	matrix metallopeptidase 10 (stromelysin 2)	11.0	Publications
23	CD44	CD44 molecule (Indian blood group)	11.0	Publications
24	GSN	gelsolin	11.0	Publications
25	CALR	calreticulin	11.0	Publications
26	CDH1	cadherin 1, type 1, E-cadherin (epithelial)	11.0	Publications
27	ACPP	acid phosphatase, prostate	11.0	Publications
28	PCNA	proliferating cell nuclear antigen	11.0	Publications
29	CFI	complement factor I	11.0	Publications
30	CLU	clusterin	11.0	Publications
31	LAMC3	laminin, gamma 3	11.0
32	LGALS1	lectin, galactoside-binding, soluble, 1	11.0	Publications
33	CGB5	chorionic gonadotropin, beta polypeptide 5	11.0	Publications
34	ENO1	enolase 1, (alpha)	11.0	Publications
35	PTGS1	prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase)	11.0	Publications
36	FASLG	Fas ligand (TNF superfamily, member 6)	11.0	Publications
37	FGF1	fibroblast growth factor 1 (acidic)	11.0	Publications
38	DNMT1	DNA (cytosine-5-)-methyltransferase 1	11.0	Publications
39	CXADR	coxsackie virus and adenovirus receptor	11.0	Publications
40	BSG	basigin (Ok blood group)	11.0	Publications
41	PTGS2	prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase)	11.0	Publications
42	CDK4	cyclin-dependent kinase 4	11.0	Publications
43	CDK1	cyclin-dependent kinase 1	11.0	Publications
44	AKR1B1	aldo-keto reductase family 1, member B1 (aldose reductase)	11.0	Publications
45	PAK1	p21 protein (Cdc42/Rac)-activated kinase 1	11.0	Publications
46	BMPR2	bone morphogenetic protein receptor, type II (serine/threonine kinase)	11.0	Publications
47	BIRC5	baculoviral IAP repeat containing 5	11.0	Publications
48	MUC1	mucin 1, cell surface associated	11.0	Publications
49	MDM2	Mdm2, p53 E3 ubiquitin protein ligase homolog (mouse)	11.0	Publications
50	KRT19	keratin 19	11.0	Publications

Pathways related to transitional cell carcinoma according to GeneDecks:

(show top 50)    (show all 167)

id	Pathway	Score	Top Affiliating Genes
1	Melanoma20	10.9	RB1, BRAF, BAD, CDKN1A, CDKN2A, CDK4
2	p53 signaling pathway20	10.5	SFN, CHEK2, BAX, CDKN1A, CDKN2A, CD82
3	Chronic myeloid leukemia20	10.5	RB1, BRAF, BCL2L1, BAD, CDKN1A, CDKN1B
4	Colorectal Cancer Metastasis36	10.5	BRAF, BIRC5, BCL2L1, BAX, MSH2, CDKN1A
5	Prostate cancer20	10.3	RB1, BRAF, BCL2, BAD, CDKN1A, CDKN1B
6	Glioma Invasiveness36	10.2	VEGFC, BDNF, CD44, ITGA5, ITGB1, FGF1
7	Focal adhesion20	10.2	BRAF, VEGFC, PAK1, KDR, BCL2, BAD
8	Actin-Based Motility by Rho Family GTPases36	10.0	PAK1, BDNF, GSN, FGFR3, IL2, GH2
9	Angiogenesis3	10.0	VHL, VEGFC, KDR, ITGA5, ITGB1, MMP2
10	Bladder cancer20	9.9	RB1, BRAF, VEGFA, VEGFC, CDKN1A, CDKN2A
11	Pathways in cancer20	9.9	RB1, VEGFA, VEGFC, BIRC5, BCL2, BCL2L1
12	Cell adhesion ECM remodeling10	9.9	CD44, ITGA5, ITGB1, MMP1, MMP10, MMP13
13	Cell adhesion_ECM remodeling41	9.7	CD44, ITGA5, ITGB1, MMP1, MMP10, MMP13
14	ErbB signaling pathway20	9.6	BRAF, PAK1, BAD, CDKN1A, CDKN1B, MAPK10
15	Akt Signaling36	9.5	KIT, VEGFC, BMPR2, FGF1, FGFR3, MET
16	14-3-3 Induced Intracellular Signaling36	9.2	VEGFC, BDNF, BAD, FGF1, FGF2, FGFR2
17	ILK Signaling36	9.0	KIT, VIM, VEGFC, BDNF, KDR, BAD
18	CREB Pathway36	8.8	KIT, BDNF, KDR, FGF1, FGFR2, FGFR3
19	Rac1 Pathway36	8.8	PAK1, BDNF, KDR, ITGA5, ITGB1, FGF1
20	PPAR Pathway36	8.8	KIT, VEGFC, ITGA5, ITGB1, FGF1, FGF2
21	p53 Mediated Apoptosis36	8.8	KIT, VEGFC, BDNF, KDR, BCL2, CHEK2
22	Apoptotic Pathways in Synovial Fibroblasts36	8.8	KIT, VEGFC, BDNF, KDR, FGF1, FGF2
23	Paxillin Interactions36	8.7	KIT, VEGFC, PAK1, BDNF, KDR, ITGA5
24	Mitochondrial Apoptosis36	8.7	KIT, VEGFC, BDNF, KDR, BCL2, BCL2L1
25	DHA Signaling36	8.7	KIT, VEGFC, BDNF, KDR, BCL2, BCL2L1
26	Renin-Angiotensin Pathway36	8.6	KIT, VEGFC, PAK1, BDNF, KDR, FGF1
27	Nuclear Receptor Activation by Vitamin-A36	8.5	KIT, VEGFC, BDNF, KDR, FGF1, FGF2
28	eIF2 Pathway36	8.4	KIT, BRAF, VEGFC, BDNF, FGF2, FGFR2
29	Activation of PKC through GPCR36	8.4	KIT, VEGFC, BDNF, KDR, FGF1, FGF2
30	Endothelin-1 Signaling Pathway36	8.3	KIT, BRAF, FGFR2, FGFR3, IL2, IL3
31	NFAT in Immune Response36	8.3	KIT, VEGFC, BDNF, KDR, FGF1, FGF2
32	Molecular Mechanisms of Cancer36	8.3	RB1, VEGFC, BMPR2, BDNF, KDR, BCL2
33	Pancreatic Adenocarcinoma36	8.3	KIT, RB1, BRAF, VEGFC, BIRC5, BDNF
34	Telomerase Components in Cell Signaling36	8.2	KIT, RB1, VEGFC, BDNF, KDR, FGF1
35	Rap1 Pathway36	8.2	BRAF, VEGFC, BDNF, ITGA5, ITGB1, FGF1
36	Activation of PKA through GPCR36	8.1	KIT, BRAF, VEGFC, BDNF, KDR, BAD
37	eNOS Signaling36	8.1	KIT, BDNF, FGF1, FGFR2, FGFR3, MET
38	Nanog in Mammalian ESC Pluripotency36	8.0	KIT, BRAF, VEGFC, BDNF, KDR, FGF1
39	Rho Family GTPases36	8.0	KIT, VIM, VEGFC, PAK1, BDNF, KDR
40	Phospholipase-C Pathway36	8.0	KIT, VEGFC, BDNF, KDR, LAMC3, ITGA5
41	p70S6K Signaling36	8.0	KIT, VEGFC, BDNF, KDR, BAD, FGF1
42	Intracellular Calcium Signaling36	7.9	KIT, VEGFC, BDNF, KDR, FGF1, FGF2
43	TGF-Beta Pathway36	7.9	VEGFC, BDNF, KDR, BCL2, BAX, CDH1
44	MAPK Family Pathway36	7.9	BRAF, VEGFC, PAK1, BDNF, KDR, BCL2
45	GPCR Pathway36	7.9	KIT, BRAF, VEGFC, PAK1, BDNF, KDR
46	Tec Kinases Signaling36	7.8	VEGFC, BMPR2, PAK1, BDNF, BCL2, BAX
47	Antioxidant Action of Vitamin-C36	7.7	KIT, VEGFC, BMPR2, BDNF, KDR, BCL2
48	JAK-STAT Pathway36	7.3	KIT, VEGFC, BDNF, KDR, BCL2, BAX
49	ERK Signaling36	7.2	KIT, BRAF, VEGFC, PAK1, LAMC3, ITGA5
50	Estrogen Pathway36	7.1	KIT, BRAF, VEGFC, BDNF, KDR, BCL2

Compounds related to transitional cell carcinoma according to GeneDecks:

(show top 50)    (show all 484)

id	Compound	Score	Top Affiliating Genes
1	sucrose32 9 18 9	14.6	BSG, CHGA, MVP, JUP, CDK4, CDK1
2	b 72332	11.3	PCNA, VIM, CHGA, MUC1, MUC16, CEACAM5
3	roscovitine32	11.1	PCNA, VIM, BIRC5, PARP1, BCL2L1, CDK1
4	dutp32	11.0	PCNA, BIRC5, CLU, PARP1, BCL2, BCL2L1
5	cyclophosphamide32 34 9 9	13.9	BCL6, MVP
6	gold32	10.9	KIT, BRAF, CHGA, MUC1, MUC16, S100A8
7	lipid32	10.8	RB1, VIM, BSG, BRAF, VEGFC, BMPR2
8	progesterone32 42 9 18 9	14.7	KIT, KISS1, PCNA, RB1, BSG, BRAF
9	4-hydroxytamoxifen32	10.7	CLU, PARP1, FASLG, ERBB2, SRC, NR1H2
10	troglitazone32 42 9 9	13.3	RB1, VDR, BIRC5, BCL2, UPK1B, UPK2
11	crcs32	10.3	RB1, BRAF, BIRC5, MUC1, S100A8, CEACAM5
12	threonine32	10.3	BMPR2, MT-ND4, CDKN1B, FGFR2, FGFR3, CCNG1
13	erlotinib32 34 9 9	13.3	KIT, VEGFA, BIRC5, KDR, CDKN1B, CDH1
14	silymarin32	10.3	PCNA, VEGFA, BIRC5, PARP1, CDK4, CDK1
15	chi 232	10.2	MTHFR, S100A8, CDH1, MLH1, MKI67, GSTM1
16	cyclic amp32 18	11.2	KLF6, RB1, BRAF, BDNF, CHGA, BAD
17	melphalan32 9 9	12.1	BIRC5, BCL2L1, CHKB, MVP, MUC16, MMP2
18	methylcellulose32	10.1	KIT, CDH1, FGF2, IL3, IL4, ENO2
19	quercetin32 42 9 18 9	14.1	BIRC5, PARP1, BCL2, BCL2L1, BAD, BAX
20	cytochalasin d32 42	11.0	VIM, PAK1, XPC, CGA, CGB5, CD44
21	n acetylcysteine32	10.0	PCNA, BIRC5, CLU, BDNF, KDR, CHEK2
22	guanine32 9 18 9	13.0	CNTN2, VDR, BIRC5, CHGA, MTHFR, CDK1
23	oxaliplatin32 34 9 9	13.0	VEGFA, BIRC5, BCL2L1, MTHFR, XRCC1, CEACAM5
24	heparin32 9 18 9	12.9	SFRP1, VIM, BSG, VEGFC, LGALS1, LGALS3
25	gf 109203x32 42	10.9	VEGFA, CDKN1A, MMP1, MMP13, FGF2, GRP
26	forskolin32 42 9 9	12.8	CNTN2, VIM, BRAF, BDNF, CHGA, MUC1
27	thyroxine32 18	10.7	PCNA, VDR, CHKB, B2M, CGA, CGB
28	gefitinib32 34 9 9	12.6	KIT, VIM, VEGFA, BIRC5, PAK1, KDR
29	butyrate32	9.6	PCNA, RB1, VIM, VDR, BIRC5, CLU
30	adriamycin32	9.5	RB1, VIM, VDR, BIRC5, BCL2, BCL2L1
31	carboplatin32 34 9 9	12.5	RB1, VEGFA, PARP1, KDR, BCL2, CHGA
32	irinotecan32 34 9 9	12.5	KIT, BRAF, VEGFA, PARP1, BCL2L1, BAX
33	2-chlorodeoxyadenosine32	9.5	KIT, BIRC5, PARP1, BCL2, BAX, B2M
34	mg 13232 42	10.4	PCNA, VDR, BIRC5, PARP1, KDR, BCL2L1
35	resveratrol32 9 18 9	12.3	PCNA, RB1, BSG, VEGFA, VDR, BIRC5
36	ascorbic acid32 18	10.3	PCNA, NAT1, VDR, BDNF, CHKB, XRCC1
37	wortmannin32 42	10.2	VIM, BRAF, BIRC5, PAK1, BDNF, KDR
38	estrogen32	9.0	KLF6, KISS1, PCNA, BSG, NAT1, NAT2
39	12-o-tetradecanoylphorbol 13-acetate32	8.9	CNTN2, RB1, BRAF, BCL6, BAD, MSR1
40	fludarabine32 9 9	10.8	BIRC5, PARP1, BCL2, BCL2L1, BAX, CDKN1B
41	norepinephrine32 9 18 9	11.5	BDNF, CHGA, CHKB, CGA, CGB5, CD40LG
42	doxorubicin32 34 9 9	11.3	KIT, VIM, CLU, PARP1, BDNF, KDR
43	hydrocortisone32 9 9	10.3	VIM, KDR, MUC1, MMP1, MMP2, FGF1
44	histamine32 18	9.0	KIT, PCNA, VIM, BDNF, CHGA, S100A8
45	cisplatin32 34 9 9	11.0	PCNA, RB1, BRAF, VEGFA, BIRC5, BIRC7
46	cyclosporin a32 42	8.6	CNTN2, BSG, VDR, CHKB, MVP, BAD
47	serine32	7.4	KLF6, CNTN2, WARS, KIT, RB1, SERPINB3
48	paclitaxel32 34 9 9	10.3	KIT, PCNA, RB1, VIM, NAT1, BRAF
49	dexamethasone32 42 34 9 9	11.0	PCNA, RB1, VIM, NAT2, VEGFA, VEGFC
50	genistein32 9 18 9	9.9	PCNA, RB1, VIM, VEGFA, VDR, BIRC5

Cellular components related to transitional cell carcinoma according to GeneDecks:

(show all 16)

id	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:005737	11.3	PTGS2, PTEN, TERT, TMOD3, PTGS1, PTHLH
2	proteinaceous extracellular matrix	GO:005578	10.9	MMP2, MMP7, MMP9, FGF1, CALR, TGFB1
3	cell surface	GO:009986	10.9	HMMR, NTRK2, PLAU, PLAUR, ABCB1, TIMP2
4	protein complex	GO:043234	10.9	PRKCA, OXA1L, TOP2A, TSC1, PTGS2, TP53
5	basolateral plasma membrane	GO:016323	10.8	SLC16A10, SLC2A1, CXADR, TGFA, ABCC1, EGFR
6	caveola	GO:005901	10.7	SRC, CTSB, SMO, TGFBR2, SLC2A1, PTGS2
7	apical plasma membrane	GO:016324	10.7	ERBB3, CTSB, PDGFRB, LZTS1, SLC7A5, SLC3A2
8	integral to plasma membrane	GO:005887	10.2	NRG3, NTRK2, TRPV1, HLA-DRA, HLA-B, EREG
9	platelet alpha granule lumen	GO:031093	10.2	KNG1, TGFB2, TGFB1, TIMP1, EGF, CLU
10	external side of plasma membrane	GO:009897	9.8	FASLG, FAS, ANXA5, CALR, CTSB, TGFBR2
11	nucleus	GO:005634	9.6	PTGS2, PTEN, TP63, TP53, PTGS1, PTHLH
12	cytosol	GO:005829	9.6	CAV1, GSTT1, GSTP1, GSTM1, GSR, GSN
13	plasma membrane	GO:005886	9.3	PTGER4, PTGS1, DAB2IP, SRC, NRG2, NRG4
14	nucleoplasm	GO:005654	9.0	NR2F1, NR1H2, PPARA, TERT, TP63, TP53
15	extracellular space	GO:005615	8.8	CLU, VEGFC, VEGFA, SFRP1, SFN, KIT
16	extracellular region	GO:005576	8.2	PSG1, TFRC, TGFB2, TGFB1, TIMP2, TIMP1

Biological processes related to transitional cell carcinoma according to GeneDecks:

(show top 50)    (show all 57)

id	Name	GO ID	Score	Top Affiliating Genes
1	negative regulation of transcription from RNA polymerase II promoter	GO:000122	11.5	NR2F1, PPARA, DAB2IP, DMAP1, PTCH1, SMAD4
2	negative regulation of cell growth	GO:030308	11.1	FGF2, ENO1, TP53, DAB2IP, SMAD4, TGFB1
3	induction of apoptosis by intracellular signals	GO:008629	11.1	APAF1, CASP3, HRAS, TP53, PRKCA, CDKN1A
4	negative regulation of apoptotic process	GO:043066	11.1	GATA6, HNF1B, GLI3, CASP3, HSPD1, CCNG1
5	positive regulation of cell migration	GO:030335	11.0	F2RL1, ERBB4, PDGFRB, EGFR, ABCC1, TGFB1
6	negative regulation of transcription, DNA-dependent	GO:045892	11.0	EZH2, CALR, GLI3, EREG, TP53, TP63
7	wound healing	GO:042060	11.0	TGFBR1, TGFB2, TGFA, PPARA, TPM1, ERBB2
8	positive regulation of cell division	GO:051781	10.9	TGFB2, TGFB1, TGFA, EREG, FGFR2, FGF3
9	apoptotic process	GO:006915	10.9	DAPK1, PTEN, TNFRSF10B, TP63, TP53, ERCC2
10	regulation of apoptotic process	GO:042981	10.9	TP53, TNFRSF10B, DAPK1, CTSB, TGFBR1, NME1
11	cellular response to hypoxia	GO:071456	10.9	GATA6, HIF1A, PTGS2, TP53, CA9, MDM2
12	positive regulation of epithelial cell proliferation	GO:050679	10.9	EGFR, TGFA, TGFB1, NME1, EPGN, ERBB2
13	positive regulation of gene expression	GO:010628	10.8	SMO, PLAUR, TGFB1, TGFB2, DNMT3B, DNMT1
14	release of cytochrome c from mitochondria	GO:001836	10.8	TP53, CASP3, BAX, BCL2L1, BCL2, CLU
15	leukocyte migration	GO:050900	10.8	SRC, THBD, CXADR, SLC7A5, SLC3A2, ROCK1
16	female pregnancy	GO:007565	10.7	PSG2, PSG1, TGFB2, TGFB1, THBD, PTHLH
17	extracellular matrix disassembly	GO:022617	10.7	TIMP2, TIMP1, MMP9, MMP7, MMP2, MMP14
18	regulation of cell proliferation	GO:042127	10.7	DNMT1, TGFBR2, NOS2, PTGS1, ERBB3, EZH2
19	activation of pro-apoptotic gene products	GO:008633	10.7	TNFRSF10B, IFI27, FAS, FASLG, BAX, BAD
20	epidermal growth factor receptor signaling pathway	GO:007173	10.6	SRC, EGF, EGFR, TGFA, TGFB1, PRKCA
21	response to organic cyclic compound	GO:014070	10.6	ANXA1, CCND1, PTGS2, CTSB, PRKCA, ENO2
22	positive regulation of peptidyl-serine phosphorylation	GO:033138	10.6	TGFB1, CAV1, MET, CD44, BCL2, PAK1
23	cell cycle arrest	GO:007050	10.5	EIF4G2, TSC1, TGFB1, TGFB2, TGFBR1, DBC1
24	organ morphogenesis	GO:009887	10.5	SYK, PTCH1, EREG, HRAS, FGFR2, FGF2
25	positive regulation of DNA replication	GO:045740	10.5	CSF2, EGFR, EREG, HRAS, CALR, IL3
26	neuron apoptotic process	GO:051402	10.4	TP63, TP53, ERBB3, CASP3, FAS, BAX
27	fibroblast growth factor receptor signaling pathway	GO:008543	10.4	FGFR3, MDM2, HRAS, PTEN, SRC, PRKCA
28	heart development	GO:007507	10.4	TGFBR2, TGFBR1, TGFB2, PPARA, PTEN, ERBB2
29	aging	GO:007568	10.4	PRKCA, TGFB2, TGFB1, TIMP1, TOP2A, PTGS1
30	response to drug	GO:042493	10.3	GATA6, NME1, DNMT3B, TGFBR2, TGFB2, CCND1
31	induction of apoptosis	GO:006917	10.3	ERCC2, TP63, PTEN, DAPK1, TGFB1, TGFB2
32	activation of cysteine-type endopeptidase activity involved in apoptotic process	GO:006919	10.3	TNFRSF10B, HSPD1, IFI27, FAS, FASLG, APAF1
33	blood coagulation	GO:007596	10.2	TGFB1, THBD, TIMP1, ABL1, EGF, NOS2
34	virus-host interaction	GO:019048	10.2	TP53, SRC, KRT8, KRT7, KRT18, KRT19
35	cytokine-mediated signaling pathway	GO:019221	10.2	HLA-B, HLA-DRA, HLA-G, RNASEL, EIF4G2, CSF3
36	positive regulation of apoptotic process	GO:043065	10.1	HSPD1, TP53, PTGS2, DAB2IP, ABL1, TOP2A
37	response to estradiol stimulus	GO:032355	10.1	ESR1, PTGS2, TGFB1, TGFB2, PRKCA, CALR
38	protein autophosphorylation	GO:046777	10.0	ERBB2, DAPK1, NTRK2, PDGFRB, EGFR, SYK
39	response to hypoxia	GO:001666	10.0	PPARA, SMAD4, NOS2, HIF1A, TGFB1, TGFB2
40	negative regulation of neuron apoptotic process	GO:043524	10.0	ERBB3, NTRK2, HIF1A, TGFA, ROCK1, HRAS
41	anti-apoptosis	GO:006916	10.0	GSTP1, IL2, FAS, ANXA5, ANXA1, TERT
42	positive regulation of ERK1 and ERK2 cascade	GO:070374	10.0	PRKCA, PDGFRB, ERBB4, HRAS, F2RL1, FGFR3
43	angiogenesis	GO:001525	9.9	EGF, HIF1A, TYMP, TGFA, TGFB2, SYK
44	positive regulation of transcription, DNA-dependent	GO:045893	9.6	PPARA, TP63, TP53, ERCC2, SMAD4, RNF20
45	negative regulation of cell proliferation	GO:008285	9.6	GLI3, VDR, VHL, SFRP1, SFN, KISS1R
46	peptidyl-tyrosine phosphorylation	GO:018108	9.6	EGF, ABL1, SYK, EPHB2, PDGFRB, SRC
47	positive regulation of cell proliferation	GO:008284	9.4	VEGFC, VEGFA, SFRP1, KIT, CSF2, TGFBR2
48	positive regulation of tyrosine phosphorylation of Stat5 protein	GO:042523	8.9	CSF2, ERBB4, IL4, IL3, IL2, KIT
49	signal transduction	GO:007165	8.8	NRG2, NR2F1, SRC, ERBB2, ERBB4, ERBB3
50	positive regulation of transcription from RNA polymerase II promoter	GO:045944	8.6	PPARA, DAB2IP, TP63, TP53, ERCC2, ESR1

Molecular functions related to transitional cell carcinoma according to GeneDecks:

(show all 11)

id	Name	GO ID	Score	Top Affiliating Genes
1	protein heterodimerization activity	GO:046982	10.4	HNF1B, ERBB3, ERBB2, TP53, EGFR, HIF1A
2	protein homodimerization activity	GO:042803	10.3	PTGS2, TERT, HLA-G, ERCC5, ERBB4, ERBB3
3	receptor signaling protein tyrosine kinase activity	GO:004716	10.2	SYK, EGFR, ERBB2, ERBB4, KDR, KIT
4	epidermal growth factor receptor binding	GO:005154	10.2	ERBB4, EREG, NRG2, EGF, TGFA, EPGN
5	enzyme binding	GO:019899	10.1	PTGS2, PLAUR, EGFR, HIF1A, TOP2A, TGFB1
6	protein kinase binding	GO:019901	10.1	CCND1, TP53, PTEN, DAB2IP, HIF1A, SYK
7	identical protein binding	GO:042802	10.0	ERBB2, TP53, TP63, SMAD4, SKP2, EGFR
8	protein binding	GO:005515	9.6	NOS2, DMAP1, PTGER4, PTCRA, PTEN, PTCH1
9	protein tyrosine kinase activity	GO:004713	9.6	SRC, PDGFRB, EGFR, ABL1, EPHB2, ERBB2
10	ATP binding	GO:005524	9.2	EGFR, PDGFRB, RNASEL, NTRK2, SRC, DAPK1
11	growth factor activity	GO:008083	9.1	NRG4, EGF, TYMP, TGFA, TGFB1, TGFB2